Clinical trials
Pancreatic Adenocarcinoma Advanced or Metastatic clinical trials
Below are recruiting pancreatic adenocarcinoma advanced or metastatic clinical trials, each written for real people, not researchers. We’re tracking 3,872 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05204147RecruitingPhase 1
Radioactive antibody for CEA-making advanced cancers
This early-phase trial tests a radioactive antibody (Ac225-DOTA-M5A) that targets CEA, a protein found on many cancer cells. It's for people with advanced or metastatic cancers that produce CEA and who have no good standard treatment options left.
Duarte, CaliforniaAges 18 years+ - NCT06770764RecruitingPhase 1
Testing ODC-IL2 for advanced solid tumors
This trial tests a new drug called ODC-IL2 for people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to help your immune system fight cancer. The study starts with small doses to find the best dose, then expands to see how well it works.
Scottsdale, ArizonaAges 18 years+ - NCT06771193Recruiting
Study of cervical cancer treatment patterns in Italy
This study looks at the types of treatments and disease characteristics in people with cervical cancer that is locally advanced (cannot be removed by surgery) or has come back or spread. It may help doctors understand how different treatments are used in Italy.
Bologna, BolognaAges 18 years+ - NCT06778031RecruitingPhase 2
Study of SHR-A1811 for HER2-positive bile duct cancer
This trial tests a new drug, SHR-A1811, for people with HER2-positive bile duct cancer that has spread or cannot be removed by surgery. It may help control the cancer if you haven't had other treatments for this stage.
Harbin, HeilongjiangAges 18–75 - NCT06805617RecruitingPhase 2
Ivonescimab for advanced salivary gland cancer
This trial tests a new drug called Ivonescimab for people with advanced salivary gland cancer that has spread or cannot be removed surgically. The goal is to see if the drug can shrink tumors or slow cancer growth.
Boston, MassachusettsAges 18 years+ - NCT06824064RecruitingPhase 2
RBS2418 for advanced metastatic colorectal cancer
This trial tests a new drug called RBS2418 for people with advanced colorectal cancer that has spread and is getting worse, even after other treatments have stopped working. The goal is to see if RBS2418 can help control the cancer.
Newark, DelawareAges 18 years+ - NCT06833866RecruitingPhase 1
Testing a natural compound with chemo for advanced colorectal cancer
This trial combines a natural substance called hydroxytyrosol (HT) with standard chemotherapy (5-FU and possibly other drugs) for people with advanced or metastatic colorectal cancer that hasn't been treated yet. The goal is to see if adding HT makes the treatment work better.
Houston, TexasAges 18 years+ - NCT06893536Recruiting
Nutrition and recovery after pancreatic cancer surgery
This study looks at how nutrition before and after surgery affects recovery for people with pancreatic cancer that can be removed. By reviewing medical records of past patients, researchers hope to learn how to better support patients through their treatment.
StrasbourgAges 18 years+ - NCT06940440RecruitingPhase 1
IFx-Hu2.0 with pembrolizumab for advanced Merkel cell carcinoma
This trial tests a new drug, IFx-Hu2.0, given alongside the immunotherapy pembrolizumab (Keytruda) for people with advanced or spreading Merkel cell carcinoma (MCC). The goal is to see if the combination helps shrink tumors and slow the disease.
Tampa, FloridaAges 18 years+ - NCT06947928RecruitingPhase 2/Phase 3
Vaccine plus immunotherapy for Merkel cell cancer
This trial tests an experimental vaccine (IFx-Hu2.0) followed by the immunotherapy drug pembrolizumab in people with advanced Merkel cell carcinoma who have not been treated with checkpoint inhibitors before. The goal is to see if this combination helps shrink or control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06952010RecruitingPhase 1
Study of XB628 alone and with zanzalintinib for advanced solid tumors
This trial tests a new drug, XB628, alone or together with another drug called zanzalintinib, in people whose advanced solid tumor has continued to grow after at least one prior treatment. The goal is to see if these combinations can shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT06951997RecruitingPhase 2
First treatment for metastatic pancreatic cancer using three drugs
This trial tests a new combination of three drugs (QL1706, chidamide, and AG) as the very first treatment for people with metastatic pancreatic cancer. The goal is to see if this combination is safe and effective, and it may offer a new option for those who have not had any prior therapy.
TianjinAges 18–75 - NCT06955988RecruitingPhase 1
Safety and early results of AST2303 for advanced lung cancer
This trial tests a new oral drug, AST2303 (ABK3376), in people with advanced non-small cell lung cancer that has not responded to other treatments. It aims to see if the drug is safe and whether it can shrink tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06975410RecruitingPhase 1/Phase 2
Trial of YH32364 for EGFR-positive solid tumors
This trial tests a new drug, YH32364, for people with advanced solid tumors that have high levels of EGFR protein. It looks at whether the drug can help when standard treatments have stopped working.
SeoulAges 18 years+ - NCT06998108RecruitingPhase 3
A new drug with fulvestrant for HR+/HER2- advanced breast cancer
This trial tests a new investigational drug called BEBT-209 combined with fulvestrant (a hormone therapy) versus placebo with fulvestrant for people with a type of breast cancer that is hormone receptor-positive and HER2-negative. It is for those whose cancer has worsened after previous hormone therapy and has spread locally or to other parts of the body.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07012031RecruitingPhase 1/Phase 2
Sotorasib and trastuzumab deruxtecan for KRAS G12C lung cancer
This trial tests a combination of two drugs, sotorasib and trastuzumab deruxtecan, for people with advanced or metastatic non-small cell lung cancer that has a KRAS G12C mutation. It may be an option if you've already had treatment with a KRAS G12C inhibitor, immunotherapy, and chemotherapy.
Sacramento, CaliforniaAges 18 years+ - NCT07024173RecruitingPhase 3
Study of HRS-8080 for advanced breast cancer
This trial tests a new drug, HRS-8080, against other standard treatments chosen by your doctor for advanced or metastatic breast cancer. It's for women who have already tried 1-2 hormone therapies and are in generally good health.
Guangzhou, GuangdongAges 18–75 - NCT07030283RecruitingPhase 1
Chemotherapy in the belly for pancreatic cancer that has spread
This trial tests a combination of chemotherapy drugs (NALIRIFOX given through a vein plus paclitaxel given directly into the abdomen) for people with pancreatic cancer that has spread to the lining of the belly but not to other organs. The goal is to see if this approach is safe and effective.
Aurora, ColoradoAges 18 years+ - NCT07038343RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial tests a new drug called AVZO-1418, either alone or with other treatments, for people with advanced solid tumors that have spread or cannot be removed. The goal is to see if the drug is safe and effective against certain types of cancer.
Gilbert, ArizonaAges 18–75 - NCT07073794RecruitingPhase 2
Home versus clinic cancer therapy for Black men with prostate cancer
This study looks at whether giving certain prostate cancer treatments at home (instead of the clinic) works as well for Black men. If you qualify, you may get your regular treatment at home with a nurse.
Jacksonville, FloridaAges 18 years+ - NCT07086768RecruitingPhase 1
BSI-082 alone or with T-DXd for advanced solid tumors
This trial tests a new drug, BSI-082, alone or with another drug (T-DXd), for people with advanced solid tumors that no longer respond to standard therapy. It aims to find the best dose and check how well it works.
San Antonio, TexasAges 18 years+ - NCT07156253RecruitingPhase 1
Study of SYN818 with olaparib for advanced solid tumors
This trial is testing a new drug, SYN818, combined with olaparib for people with advanced solid tumors that have certain genetic changes (BRCA mutations or related DNA repair problems). It may be an option if you have ovarian or HER2-negative breast cancer and other treatments are no longer working.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07170995RecruitingPhase 3
Study of SHR-8068 with adebrelimab and chemo for lung cancer
This trial tests a new combination of drugs (SHR-8068 plus adebrelimab and chemotherapy) against another approved combination for people with advanced non-small cell lung cancer who have not had treatment yet. The goal is to see which combination works better.
Jinan, ShandongAges 18–75 - NCT07174570RecruitingPhase 2
Celecoxib with immunotherapy for advanced liver cancer
This trial tests a combination of two immunotherapy drugs (durvalumab and tremelimumab) plus a pain reliever (celecoxib) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this three-drug combination works better than standard treatments.
Atlanta, GeorgiaAges 18 years+
Hear when a new Pancreatic Adenocarcinoma Advanced or Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatic adenocarcinoma advanced or metastatic?
- Yes. Clin2 currently lists 3,872 recruiting pancreatic adenocarcinoma advanced or metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatic adenocarcinoma advanced or metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatic adenocarcinoma advanced or metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.